408 related articles for article (PubMed ID: 30833371)
1. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
[TBL] [Abstract][Full Text] [Related]
2. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
[TBL] [Abstract][Full Text] [Related]
3. HbA
Danne T; Cariou B; Banks P; Brandle M; Brath H; Franek E; Kushner JA; Lapuerta P; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2018 Sep; 41(9):1981-1990. PubMed ID: 29937431
[TBL] [Abstract][Full Text] [Related]
4. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Danne T; Pettus J; Giaccari A; Cariou B; Rodbard H; Weinzimer SA; Bonnemaire M; Sawhney S; Stewart J; Wang S; Castro RC; Garg SK
Diabetes Technol Ther; 2019 Sep; 21(9):471-477. PubMed ID: 31335194
[No Abstract] [Full Text] [Related]
5. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
Buse JB; Garg SK; Rosenstock J; Bailey TS; Banks P; Bode BW; Danne T; Kushner JA; Lane WS; Lapuerta P; McGuire DK; Peters AL; Reed J; Sawhney S; Strumph P
Diabetes Care; 2018 Sep; 41(9):1970-1980. PubMed ID: 29937430
[TBL] [Abstract][Full Text] [Related]
6. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
Rodbard HW; Giaccari A; Cariou B; Garg S; Davies MJ; Seth K; Sawhney S
Diab Vasc Dis Res; 2021; 18(1):1479164121995928. PubMed ID: 33611925
[TBL] [Abstract][Full Text] [Related]
7. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Musso G; Gambino R; Cassader M; Paschetta E
BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
[TBL] [Abstract][Full Text] [Related]
9. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
10. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Peters AL; McGuire DK; Danne T; Kushner JA; Rodbard HW; Dhatariya K; Sawhney S; Banks P; Jiang W; Davies MJ; Lapuerta P
Diabetes Care; 2020 Nov; 43(11):2713-2720. PubMed ID: 32928957
[TBL] [Abstract][Full Text] [Related]
11. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Garg SK; Henry RR; Banks P; Buse JB; Davies MJ; Fulcher GR; Pozzilli P; Gesty-Palmer D; Lapuerta P; Simó R; Danne T; McGuire DK; Kushner JA; Peters A; Strumph P
N Engl J Med; 2017 Dec; 377(24):2337-2348. PubMed ID: 28899222
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Baker C; Wason S; Banks P; Sawhney S; Chang A; Danne T; Gesty-Palmer D; Kushner JA; McGuire DK; Mikell F; O'Neill M; Peters AL; Strumph P
Diabetes Obes Metab; 2019 Nov; 21(11):2440-2449. PubMed ID: 31264767
[TBL] [Abstract][Full Text] [Related]
14. Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
Powell DR; Zambrowicz B; Morrow L; Beysen C; Hompesch M; Turner S; Hellerstein M; Banks P; Strumph P; Lapuerta P
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1235-49. PubMed ID: 31837264
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
Rodbard HW; Peters AL; Slee A; Cao A; Traina SB; Alba M
Diabetes Care; 2017 Feb; 40(2):171-180. PubMed ID: 27899497
[TBL] [Abstract][Full Text] [Related]
16. Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
Danne T; Joish VN; Afonso M; Banks P; Sawhney S; Lapuerta P; Davies MJ; Buse JB; Lin D; Reaney M; Guillonneau S; Snoek FJ; Bailey TS; Polonsky WH
Diabetes Technol Ther; 2021 Jan; 23(1):70-77. PubMed ID: 32721228
[No Abstract] [Full Text] [Related]
17. Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
Bode BW; Cengiz E; Wadwa RP; Banks P; Danne T; Kushner JA; McGuire DK; Peters AL; Strumph P; Sawhney S
Diabetes Technol Ther; 2021 Jan; 23(1):59-69. PubMed ID: 32640846
[No Abstract] [Full Text] [Related]
18. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Nishimura R; Tanaka Y; Koiwai K; Inoue K; Hach T; Salsali A; Lund SS; Broedl UC
Cardiovasc Diabetol; 2015 Jan; 14():11. PubMed ID: 25633683
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
van Raalte DH; Bjornstad P; Persson F; Powell DR; de Cassia Castro R; Wang PS; Liu M; Heerspink HJL; Cherney D
Diabetes Care; 2019 Oct; 42(10):1921-1929. PubMed ID: 31371432
[TBL] [Abstract][Full Text] [Related]
20. Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Rodbard HW; Giaccari A; Lajara R; Stewart J; Strumph PS; Oliveira J; Lapuerta P; Castro R
Diabetes Obes Metab; 2020 Nov; 22(11):2089-2096. PubMed ID: 32618383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
